Asgard Therapeutics AB, a privately-held preclinical biotech based in Sweden announced on 5 September the publication in Science of preclinical data for its lead gene therapy programme AT-108. The programme is an autologous therapy that reprogrammes tumour cells into a subset of dendritic cells thereby mounting a cytotoxic T cell response in cancer. The study, co-led by Asgard and the scientists at the Pereira Lab at Lund University in Sweden, showed that it was possible to reprogramme dendritic cells in mice that were resistant to treatment with checkpoint inhibitors.
